EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results

Bianca Maria Piraccini iD, Stephano Cedirian iD, Francesca Pampaloni iD, Luca Rapparini iD, Federico Quadrelli, Francesca Bruni iD, Lorenzo Ala, Maria Cristina Acri, Alfredo Rossi iD, Giovanni Pellacani, Francesco Lacarrubba iD, Federica Dall'Oglio und 48 weitere

Journal of the European Academy of Dermatology and Venereology · 2026-02 · 40 (2) · 224-231

DOI: 10.1111/jdv.70067 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 23.09.2025. Verfasst von Bianca Maria Piraccini und 59 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy. Hauptthemen laut MEDLINE: Alopecia Areata, Purines, Sulfonamides, Azetidines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alopecia areata (AA) is an autoimmune condition leading to hair loss. Baricitinib, a Janus kinase (JAK) inhibitor, has demonstrated efficacy in controlled clinical trials, but real‐world data on its long‐term effectiveness and safety remain limited.

Objectives

This study aimed to assess the real‐life effectiveness and safety of baricitinib 4 mg daily in Italian adult patients with severe AA over a 48‐week treatment period.

Methods

We conducted a 48‐week retrospective, observational, multicenter study across 27 Italian university hospitals. Adult patients (18–65 years) with severe AA (Severity of Alopecia Tool [SALT] score ≥ 50) who initiated baricitinib 4 mg daily treatment between November 2022 and October 2023 were included. Effectiveness was measured by the percentage of patients achieving SALT ≤20 at week 48. Secondary outcomes included changes in mean SALT score, trichoscopic findings, patient‐reported quality of life (Skindex‐16, Hospital Anxiety and Depression Scale [HADS]), and Clinician‐Reported Outcomes (ClinRO) for eyebrows and eyelashes. Adverse events were also documented.

Results

A total of 253 patients (66.8% females, mean age 40.0 ± 12.6 years) were included. By week 48, 63.2% achieved SALT ≤20, and 75.5% achieved SALT ≤30. The mean SALT score significantly decreased from 93.7 ± 14.1 at baseline to 26.5 ± 33.0 at week 48 ( p < 0.001). Trichoscopic assessment showed a decline in yellow dots (97.6%–50.2%), black dots (43.5%–9.1%), and dystrophic hairs (14.6%–4.3%), whilst regrowing hairs increased (7.1%–80.2%). Skindex‐16 scores improved significantly (57.1 ± 25.0 to 30.0 ± 17.8, p < 0.001), as did HADS Anxiety (8.21 ± 9.38 to 4.62 ± 4.21, p < 0.001) and HADS Depression (6.36 ± 4.55 to 3.70 ± 4.11, p < 0.001). Adverse events were reported in 9.4% of patients.

Conclusions

This real‐world study confirms the effectiveness of baricitinib in achieving significant hair regrowth and improving psychological well‐being in severe AA patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataPurinesSulfonamidesAzetidinesPyrazolesJanus Kinase InhibitorsHumansAdultFemaleMaleMiddle AgedRetrospective StudiesYoung AdultAdolescentSeverity of Illness IndexTreatment OutcomeAgedQuality of LifeItaly

Stichwörter der Autor:innen

HADSJanus kinase inhibitorsSKINDEX‐16alopecia areatabaricitinibtrichoscopy

Substanzen

baricitinibPurinesSulfonamidesAzetidinesPyrazolesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
  • Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Department of Clinical, Internal, Anesthesiological and Cardiovascular Science - Dermatology Section, Sapienza University of Rome, Rome, Italy.
  • Dermatology Clinic, University of Catania, Catania, Italy.
  • Chair, Dermatology Clinic, University of Catania, Catania, Italy.
  • Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

ORCID-Profile: Bianca Maria Piraccini, Stephano Cedirian, Francesca Pampaloni, Luca Rapparini, Francesca Bruni, Alfredo Rossi, Francesco Lacarrubba, Luciano Foggia, Laura Diluvio, Giacomo Caldarola, Giampiero Girolomoni, Francesco Bellinato, Paolo Gisondi, Francesca Prignano, Stefania Barruscotti, Edoardo de Simoni, Francesca Ambrogio, Angelo Valerio Marzano, Andrea Sechi, Luca Valtellini, Simone Ribero, Pietro Quaglino, Riccardo Balestri, Raffaele Dante Caposiena, Chiara Caponio, Elisa Cinotti, Emanuele Trovato, Valentina Dini, Flavia Manzo Margiotta

Förderung

  • Eli Lilly and Company

Zitieren

APA

Piraccini, B. M., Cedirian, S., Pampaloni, F., Rapparini, L., Quadrelli, F., Bruni, F., Ala, L., Acri, M. C., Rossi, A., Pellacani, G., Lacarrubba, F., Dall'Oglio, F., Micali, G., Foggia, L., Cantelli, M., Nappa, P., Diluvio, L., Bianchi, L., Luigi, N., …, & Manzo Margiotta, F. (2026). Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results. Journal of the European Academy of Dermatology and Venereology, 40(2), 224-231. https://doi.org/10.1111/jdv.70067

Vancouver

Piraccini BM, Cedirian S, Pampaloni F, Rapparini L, Quadrelli F, Bruni F, et al. Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results. Journal of the European Academy of Dermatology and Venereology. 2026;40(2):224-231. doi:10.1111/jdv.70067

BibTeX
@article{Piraccini2026,
  author = {Piraccini, Bianca Maria and Cedirian, Stephano and Pampaloni, Francesca and Rapparini, Luca and Quadrelli, Federico and Bruni, Francesca and Ala, Lorenzo and Acri, Maria Cristina and Rossi, Alfredo and Pellacani, Giovanni and Lacarrubba, Francesco and Dall'Oglio, Federica and Micali, Giuseppe and Foggia, Luciano and Cantelli, Mariateresa and Nappa, Paola and Diluvio, Laura and Bianchi, Luca and Luigi, Naldi and Bolzon, Anna and Peris, Ketty and Caldarola, Giacomo and Girolomoni, Giampiero and Marangoni, Francesca and Bellinato, Francesco and Gisondi, Paolo and Silvi, Gianmarco and Prignano, Francesca and Pimpinelli, Nicola and Tomasini, Carlo and Barruscotti, Stefania and Simonetti, Oriana and de Simoni, Edoardo and Ambrogio, Francesca and Foti, Caterina and Boccaletti, Valeria and Fraghì, Alessandro and Marzano, Angelo Valerio and Mattioli, Maria Alessandra and Ferrucci, Silvia and Sechi, Andrea and Valtellini, Luca and Barbareschi, Mauro and Gallo, Giuseppe and Ribero, Simone and Quaglino, Pietro and Di Corteranzo, Isotta Giunipero and Balestri, Riccardo and Pagliarello, Calogero and Caposiena, Raffaele Dante and Zalaudek, Iris and Vagnozzi, Emanuele and Fargnoli, Maria Concetta and Caponio, Chiara and Rubegni, Pietro and Cinotti, Elisa and Trovato, Emanuele and Romanelli, Marco and Dini, Valentina and Manzo Margiotta, Flavia},
  title = {Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {2},
  pages = {224--231},
  doi = {10.1111/jdv.70067}
}
Kostenlos starten →